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Abstract
Background: Interleukin-33 (IL-33) and ST2 have been demonstrated to be associated with liver damage. However,
their potential value in hepatitis B virus (HBV) infection remains unknown. This study was designed to investigate
the change of serum IL-33 and ST2 levels in the natural course of chronic HBV infection.
Methods: A total of 120 patients with chronic hepatitis B (CHB), 20 chronic hepatitis B virus carriers in immunotolerant
phase and 28 healthy controls were enrolled in this study. All patients with CHB were divided into four groups according
to their serum ALT levels. The serum levels of IL-33 and ST2 of all participants were determined by enzyme-linked
immunosorbent assay, and compared between each two out of those six groups.
Results: No significant differences were found in serum levels of IL-33 and ST2 between the group of CHB with ALT 1–2
upper limit of normal and the healthy controls (P = 0.354 for IL-33 and P = 0.815 for ST2). Other than that, there were
significant differences when serum levels of IL-33 and ST2 were compared between any other two out of those six
groups (P < 0.05, respectively). The overall correlation analysis indicated that changes of serum IL-33 and ST2 levels
were positively associated with ALT levels in patients with chronic HBV infection (rs = 0.879, P < 0.001 for IL-33 and
rs = 0.923, P < 0.001 for ST2). No significant differences were found when the serum levels of ALT, IL-33 and ST2 were
compared between patients with HBeAg-positive CHB and HBeAg-negative CHB.
Conclusions: Our study revealed that the serum levels of IL-33 and ST2 varied in different courses of chronic hepatitis
B virus infection. The serum levels of IL-33 and ST2 elevated as serum ALT levels increased in patients with CHB. They
might indicate liver damage for patients with CHB, just like ALT.
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Background
Interleukin-33 (IL-33), a new member of the IL-1 family,
induced the production of pro-inflammatory and T
helper-2 (Th2)-associated cytokines. ST2 was to weaken
Th2 inflammatory responses as its receptor [1]. Hepatitis
B virus (HBV) infection is still a major health problem
worldwide. There are approximately 350 million people
chronically infected with HBV globally, and they are at
great risk of developing liver cirrhosis and hepatocellular
carcinoma. About 5 % of adulthood and over 90 % of
infants and young children who are infected with HBV
will evolve chronicity [2]. Many patients with chronic
hepatitis B (CHB) ultimately progress to liver cirrhosis
and hepatocellular carcinoma [3, 4]. Previous studies
showed that the interaction of HBV, hepatocytes and the
host immune system determines the persistence of HBV
infection and chronic inflammation [5]. The immune
system was known to be suppressed by the viral infec-
tion and related hepatocyte injuries [6, 7]. Although
experimental evidence suggested that antigen-specific
Th1 immunity and pro-inflammatory cytokines played
an important role in the HBV related liver injury and
clearance of viruses [8, 9], serum IL-33 levels were asso-
ciated with liver damage of patients with CHB [10],
serum levels of IL-33 and soluble ST2 elevated in liver
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failure, which could be a sign of immune hyperactiva-
tion, and/or a mechanism to down-regulate inflamma-
tion [1]. Soluble ST2 may be useful to discern acute
from chronic hepatic failure or to monitor the course
and the severity of the disease. It is widely accepted that
the adaptive immune responses play major roles in the
clearance of HBV infection. However, the role of innate
immunity during HBV infection appears not to be well
understood, which can be attributed to the fact that the
recruitment of patients in the very early, asymptomatic
phase of HBV infection is very difficult [11, 12].
Remarkable progress had been made in the under-
standing of the natural history of chronic HBV infection.
The natural course of chronic HBV infection was per-
ceived as consisting of 4 phases: immune tolerance, im-
mune clearance (HBeAg-positive chronic hepatitis B),
inactive carrier state, and reactivation (HBeAg-negative
chronic hepatitis B) [13]. Although serum levels of IL-33
and ST2 were up-regulated in liver failure and CHB, the
relevance of serum levels of both molecules and patients
with hepatitis B virus infection needed further research
and serum alanine aminotransferase (ALT) activity is an
important marker for liver damage in patients with
CHB. We therefore sought to investigate the serum mea-
surements of IL-33 and ST2 in patients with chronic
hepatitis B virus infection and study the relationship of
IL-33 and ST2 with ALT and HBeAg. We examined the
levels of serum IL-33, ST2 and ALT in patients with
CHB, chronic hepatitis B virus carriers in immunotoler-
ant phase and healthy controls (HC) so that we could
determine whether IL-33 and ST2 had relevance with
chronic HBV infection in our study.
Methods
Patients
A total of 120 patients with CHB, 20 chronic hepatitis B
virus carriers in immunotolerant phase, and 28 HC were
successively conscribed at the outpatient and inpatient
services in Qilu Hospital of Shandong University and
Qingdao Municipal Infectious Disease Hospital from
September 2012 through May 2014. The patients with
CHB and chronic hepatitis B virus carriers in immuno-
tolerant phase were defined according to the criteria of
Asian-Pacific consensus statement on the management
of chronic hepatitis B [14]. All patients with CHB were
stratified into four groups according to their serum
levels of ALT, including ALT1-2 upper limit of normal
(ULN), ALT2-5ULN, ALT5-10ULN, ALT > 10ULN. The
number of patients with CHB in each group was calcu-
lated based on the data obtained from preliminary ex-
periment by using PASS 11. Besides, all patients with
CHB were divided into two groups of 65 patients with
HBeAg-positive chronic hepatitis B and 55 patients with
HBeAg-negative chronic hepatitis B according to their
serum HBeAg. Patients with chronic HBV infection were
confirmed positive for HBsAg, HBeAg or HBeAb and
detectable HBV virus for at least 12 months [13]. People
who had comorbidities such as history of infection,
hodiernal hepatitis A, C, D and E viruse infection, hu-
man immunodeficiency virus infection, autoimmune
hepatitis, metabolic liver disease et al., were eliminated.
All patients had not received any therapy of liver injury
or been exposed to obvious liver damage compound.
Written informed consent was obtained from individ-
ual participants, and the study was approved by Ethical
Committee of Qilu Hospital of Shandong University and
Qingdao Municipal Infectious Disease Hospital.
Laboratory assays
Sera were extracted after blood samples were taken from
all the participants and then stored at −80 °C till needed.
The measurements of serum IL-33 and ST2 in all partic-
ipants were determined by enzyme-linked immunosorb-
ent assay (ELISA) using human IL-33 and ST2 ELISA
Kits (Immunoway Biotechnology, USA) according to the
manufacturer’s instruction. The measurements of serum
IL-33/ST2 in individual samples were calculated accord-
ing to the standard curve established using the recom-
binant IL-33 and ST2 provided.
HBV-related HBsAg, HBsAb, HBcAb, HBeAg, and
HBeAb were detected by an electro-chemiluminescence
immunoassay using Roche kits (Roche Diagnostics,
Germany) according to the manufacturer’s instruction.
The level of serum ALT was detected by Velocity
method using big biochemistry automatic analyzer
(Olympus 2700, Japan).
The serum HBVDNA levels were measured by nested
reverse transcription polymerase chain reaction (PCR)
quantitative assay using a luciferase quantitization detec-
tion kit, following the protocols (Roche Amplicor,
Germany). The detection limit of viral DNA was 300
copies/ml [12, 15].
Statistical analysis
The data were expressed as the median (inter-quartile
range). The differences between the groups were analyzed
by Mann-Whitney U-test and overall correlation between
ALT and IL-33, as well as ST2 were analyzed by Spearman’s
rank correlation test using SPSS17.0 software. A two-side P
value of < 0.05 was considered statistically significant.
Results
There were no significant differences in the distribution
of age or gender among the six groups of participants,
and there were no significant differences in the serum
HBVDNA levels among the five groups of chronic HBV
infection (Table 1).
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The serum levels of ALT, IL-33 and ST2 in the six
groups of participants were listed in Table 2. The serum
levels of IL-33 and ST2 were compared between each two
out of those six groups. No significant difference was
found in serum IL-33 levels between the CHB ALT1-
2ULN group and the HC (P = 0.354). Other than that,
there were significant differences when serum IL-33 levels
were compared between any other two out of those six
groups (P < 0.05, respectively). Although the P values were
significant in above comparisons, the direction of the dif-
ference varied. IL-33 levels were significantly higher in
healthy control group compared to the group in immuno-
tolerant phase but it was significantly lower in healthy
control group compared to the groups with ALT >2 times
high (Fig. 1). In terms of serum ST2 concentrations, a
similar trend was also observed. There were significant
differences in serum ST2 levels between any other two
out of those six groups (P < 0.05, respectively), except for
those between the CHB ALT1-2ULN group and the HC
(P = 0.815). Although the P values were significant in
above comparisons, the direction of the difference varied.
ST2 levels were significantly higher in healthy control
group compared to the group in immunotolerant phase
but it was significantly lower in healthy control group
compared to the groups with ALT >2 times high (Fig. 2).
Next, the overall correlations between serum ALT
and IL-33, as well as ST2 were analyzed. The result
indicated that changes of serum IL-33 and ST2 levels
were positively associated with ALT levels in patients
with chronic HBV infection (rs = 0.879, P < 0.001 for
IL-33; rs = 0.923, P < 0.001 for ST2). However, there
were no significant correlations between ALT and IL-
33, or ST2 in healthy controls (rs = −0.134, P = 0.497
for IL-33; rs = −0.012, P = 0.952 for ST2) (Fig. 3).
Finally, when the levels of serum ALT [207 (84.5,
427.5) vs 182 (76, 460)], IL-33 [22.13 (9.69, 51.57) vs
18.13 (8.76, 45.7)] and ST2 [41.78 (12.49, 147.20) vs
26.58 (11.32, 134.52)] were compared between the group
with HBeAg-positive chronic hepatitis B and the group
with HBeAg-negative chronic hepatitis B, no significant
differences were found (P = 0.635 for ALT, P = 0.456 for
IL-33, and P = 0.413 for ST2) (Fig. 4).
Discussions
The natural course of chronic HBV infection had been
treated as being comprised of 4 phases: immune tolerance,
immune clearance (HBeAg-positive chronic hepatitis B),
inactive carrier state, and reactivation (HBeAg-negative
chronic hepatitis B). Understanding the dynamic nature of
chronic HBV infection was crucial in the management of
Table 1 The demographic and clinical features of all the participants
Parameters CHB(ALT1-2ULN) CHB(ALT2-5ULN) CHB(ALT5-10ULN) CHB(ALT≥ 10ULN) CHBVIT HC
NO. 30 30 30 30 20 28
Age (years)
Median (inter-quartile range) 36.0 (26.0–41.5) 32.5 (25.8–37.5) 33.0 (25.8–38.5) 36.5 (26.0–42.0) 32.0 (27.3–35.8) 32.0 (24.0–37.5)
Sex N (%)
Male 18 (60) 20 (67) 21 (70) 19 (64) 12 (67) 18 (64)
Female 12 (40) 10 (33) 9 (30) 11 (36) 8 (33) 10 (36)
HBVDNA (log10 copies/mL)
Median (inter-quartile range) 7.4 (6.2–7.6) 7.3 (6.1–7.5) 6.4 (5.7–7.0) 6.3 (5.7–6.6) 7.5 (6.7–7.7) NA
HBeAg, pos/neg 15/15 16/14 18/12 16/14 20/0 0/28
Normal values: ALT: 1ULN = 40 IU/L. The lower limit of detection: HBVDNA 300 copies/ml. Data were expressed as median and inter-quartile range or arithmetic
mean and standard deviation (SD)
ALT alanine aminotransferase, CHB chronic hepatitis B, CHBVIT chronic hepatitis B virus carriers in immuno-tolerant phase, HBeAg hepatitis B e antigen, HBsAg hepatitis B
surface antigen, HBV DNA hepatitis B virus DNA; HC healthy control, ULN, upper limit of normal
Table 2 Serum levels of ALT, IL-33 and ST2
Groups NO. ALT (IU/L) IL-33 (pg/ml) ST2 (pg/ml)
HC 28 26.0 (23.3–31.5) 9.6 (6.6–12.7) 10.6 (6.5–13.6)
CHBVIT 20 26.5 (22.5–34.8) 5.3 (3.6–7.9) 6.1 (3.7–10.8)
CHB (ALT1-2ULN) 30 57.5 (49.0–69.8) 7.8 (4.5–10.9) 9.9 (6.2–13.2)
CHB (ALT2-5ULN) 30 117.0 (95.0–145.3) 14.8 (8.4–24.6) 19.7 (11.8–30.2)
CHB (ALT5-10ULN) 30 268.0 (237.5–319.5) 29.9 (11.8–21.8) 80.9 (33.6–69.7)
CHB (ALT≥ 10ULN) 30 1005.0 (637.0–1558.5) 79.5 (49.7–177.9) 255.4 (165.8–536.6)
Normal values: ALT: 1ULN = 40 IU/L. Data were expressed as median (inter-quartile range)
ALT alanine aminotransferase, CHB chronic hepatitis B, CHBVIT chronic hepatitis B virus carriers in immuno-tolerant phase, HC healthy control, ULN upper limit of normal
Huan et al. BMC Infectious Diseases  (2016) 16:200 Page 3 of 8
HBV carriers and underscored the need for long-term
monitoring [13]. IL-33 was a member of the IL-1 family by
classics appraisal. ST2 is a receptor for IL-33. Their mul-
tiple variants like ST2L or ST2V exist through alternative
splicing. The main biological properties of IL-33 were to
drive production of pro-inflammatory and Th2-associated
cytokines in mast cells and Th2 lymphocytes [16, 17].
Aditionally, recent evidence suggested that IL-33
belonged to the larger family of damage-associated
molecular pattern molecules and functioned as an “alar-
min” similar to high-mobility-group-protein B1 (HMGB1)
[16]. ST2 stimulated MYD88, IRAK1, IRAK4, and TRAF6
by phosphorylation of MAPK3/ERK1 and/or MAPK1/
ERK2, MAPK14, and MAPK8, Whereas ST2L exerted pro-
inflammatory effects of IL-33. Increased serum levels of
soluble ST2 had been reported in conditions like sepsis
and dengue virus infection [18, 19]. Moreover, in murine
inflammatory models, the production of pro-inflammatory
cytokines preceded ST2 expression [20, 21]. Additionally,
soluble ST2 could diminish the formation of inflammatory
mediators [21, 22]. Hepatic over-expression of IL-33 had
been detected in patients with liver fibrosis, chronic hepa-
titis B and hepatic failure. A previous study provided evi-
dence for elevated levels of IL-33 and soluble ST2 in liver
failure, which could be a sign of immune hyperactivation,
and/or a mechanism to down-regulate inflammation. Espe-
cially, soluble ST2 may be useful to discern acute from
chronic hepatic failure or to monitor the course and the se-
verity of the disease [1]. Recent studies revealed that the
levels of serum IL-33 were elevated in patients with
Fig. 1 a Comparsions of IL-33 between healthy controls (HC) and the rest five groups. b Comparisons of IL-33 between chronic hepatitis B virus
carriers in immuno-tolerant phase (CHBVIT) and the four groups of patients with CHB. c Comparisons of IL-33 between CHBALT1-2ULN group and
the rest three groups of patients with CHB. d Comparisons of IL-33 between CHBALT2-5ULN group and CHBALT5-10ULN group, between CHBALT2-5ULN
group and CHBALT > 10ULN group, between CHBALT5-10ULN group and CHBALT > 10ULN group
Huan et al. BMC Infectious Diseases  (2016) 16:200 Page 4 of 8
chronic hepatitis C and were dropped significantly after
treatment with interferon, and Wang et al. found that there
was a significant correlation between IL-33 and ALT con-
centration in chronic hepatitis C [23, 24]. Other studies
suggested that IL-33 participated in the pathogenic process
of acute hepatitis induced by Con-A [25, 26] and IL-33
overexpression was associated with the development of
HBV/HCV-related liver fibrosis [27]. Another study found
that serum IL-33 levels in patients with CHB were signifi-
cantly higher than those in healthy controls. Besides, treat-
ment with adefovir dipivoxil to inhibit the replication of
HBV dramatically decreased the levels of serum IL-33 in
patients with CHB. These confirmed that IL-33 could play
a significant role in the progression of CHB and the data
suggested that IL-33 might be a pathogenic factor in the
pathogenic process of CHB patients, but no correlation
was found between the levels of IL-33 and ALT or AST in
their study. Further, serum ST2 levels were significantly
higher in patients with CHB than those in healthy controls.
Treatment with adefovir dipivoxil for 12 weeks did not sig-
nificantly change the levels of serum ST2 [10]. A previous
study had shown that serum ST2 levels in patients with
acute liver failure were higher than those in patients with
chronic liver failure and HC [1]. It was possible that high
levels of serum ST2 were an early marker for liver injury,
while high levels of serum IL-33 may be associated with
the development and progression of liver fibrosis and dam-
age [27]. Another study showed that the dendritic cells
Fig. 2 a Comparisons of ST2 between healthy controls (HC) and the rest five groups. b Comparisons of ST2 between chronic hepatitis B virus carriers in
immuno-tolerant phase (CHBVIT) and the four groups of patients with CHB. c Comparisons of ST2 between CHBALT1-2ULN and the rest three groups of
patients with CHB. d Comparisons of ST2 between CHBALT2-5ULN group and CHBALT5-10ULN group, between CHBALT2-5ULN group and CHBALT >
10ULN group, between CHBALT5-10ULN group and CHBALT > 10ULN group
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responded directly to IL-33 through ST2. The IL-33 and
DC interaction may represent a new pathway to initiate
Th2-type immune responses [28].
Our study showed that the serum levels of IL-33 and
ST2 of the chronic hepatitis B virus carriers in immu-
notolerant phase were significantly lower than those of
the HC (P = 0.007 for IL-33 and P = 0.039 for ST2). The
serum levels of IL-33 and ST2 in patients with CHB
ALT1ULN-2ULN group were lower when compared
with those in the HC, however, the difference was not
significant (P = 0.354 for IL-33 and P = 0.815 for ST2).
The serum levels of IL-33 and ST2 in patients with
CHB ALT ≥ 2ULN groups were significantly higher than
those in the HC, respectively (P <0.05, respectively).
Changes of serum IL-33 and ST2 levels were found to
be positively associated with ALT levels in patients with
chronic HBV infection (rs = 0.879, P < 0.001 for IL-33;
rs = 0.923, P < 0.001 for ST2). However, there was no
significant correlation between ALT and IL-33, or ST2
in healthy controls (rs = −0.134, P = 0.497 for IL-33;
rs = −0.012, P = 0.952 for ST2). There were no signifi-
cant differences in the serum levels of IL-33 and ST2
between patients with HBeAg-positive CHB and those
with HBeAg-negative CHB. Our data provided evi-
dence that serum levels of IL-33 and ST2 elevated
with the increase of ALT levels in patients with CHB,
and reduced in patients with CHB ALT1-2ULN and
chronic hepatitis B virus carriers in immunotolerant
phase.
There were several limitations with our study. We did
not carry out any multivariate analysis of all parameters
that might associate with serum IL-33 and ST2 levels
Fig. 3 a The overall correlation between ALT and IL-33 in patients with chronic HBV infection. b The overall correlation between ALT and ST2 in
patients with chronic HBV infection. c The overall correlation between ALT and IL-33 in healthy controls. d The overall correlation between ALT
and ST2 in healthy controls
Fig. 4 a Comparisons of ALT between EAPCHB (HBeAg-positive chronic hepatitis B) group and EANCHB (HBeAg-negative chronic hepatitis B)
group. b Comparisons of IL-33 between EAPCHB group and EANCHB group. c Comparisons of ST2 between EAPCHB group and EANCHB group
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due to the small sample size. Besides, we didn’t conduct
liver biopsy so that we did not figure out the source for
IL-33 and ST2 through histopathological examinations.
Although more detailed studies were necessary to deter-
mine the role and mechanisms of IL-33 and ST2 in the
pathogenic process of chronic hepatitis B virus infection,
our novel findings might provide new insights into un-
derstanding the role of IL-33 and ST2 in the pathogen-
esis of chronic hepatitis B virus infection. We speculated
that IL-33 and ST2 could be used as an indicator to
judge the patient's condition, which could help doctors
choose antiviral drugs for the patients and assess the
therapeutic effects. We will conduct further study to in-
vestigate the changes of serum IL-33 and ST2 after anti-
viral treatment in future.
Conclusions
In conclusion, our data indicated that serum levels of
IL-33 and ST2 elevated with the increase of ALT levels
in patients with CHB. The serum levels of IL-33 and
ST2 varied in different courses of chronic hepatitis B
virus infection. We surmised that IL-33 and ST2 might
indicate liver damage of patients with chronic hepatitis
B, just like ALT. They were associated with the natural
course of chronic hepatitis B virus infection.
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